Optimizing local treatments for ALK-positive lung cancer on brigatinib
Part of Cancer, Lungs & breathing clinical trials.
This trial is for people with advanced ALK-positive lung cancer who are already taking the targeted therapy brigatinib and have a few remaining spots of cancer. It tests whether adding local treatments (like surgery, focused radiation, or ablation) to the remaining spots can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with stage 3 or 4 non-small cell lung cancer that has an ALK gene change.
- You cannot have had any previous targeted therapy (TKI) for ALK.
- You must have been on brigatinib for at least 3 to 9 months and your cancer is either stable or has shrunk, but not completely gone.
- You should have 5 or fewer cancer spots (metastases) in your body, and no more than 2 in one organ.
- You must be healthy enough to have local treatments like surgery, focused radiation, or heat/cold ablation for those spots.
- Your liver, kidney, and blood counts need to be within certain ranges, and you must be willing to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests lorlatinib as a treatment before surgery for people with a type of lung cancer called non-small cell lung cancer that has an ALK gene change (ALK-positive). The goal is to understand why some tumors respond and others may not, using advanced genetic tests.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
This study tests if the targeted drug lorlatinib works better than the usual combination of chemotherapy and radiation for people with a specific type of advanced lung cancer that has a change in the ALK gene. It aims to shrink tumors and stop them from growing.
This study looks at the genetic changes in ALK-positive lung cancer over time. It is for people who have already started one of three targeted treatments (alectinib, brigatinib, or lorlatinib) and are willing to provide extra tissue or blood samples for testing.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.